Migratory Polyarthritis Associated With Clopidogrel: A Case Report
Clopidogrel, a selective thienopyridine, is used for secondary prevention of major adverse cardiovascular events. Some studies have reported inflammatory arthritis as a rare adverse effect of Clopidogrel. A 47-year-old male underwent percutaneous coronary intervention and was subsequently prescribe...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2024-12-01
|
| Series: | Acta Medica Iranica |
| Subjects: | |
| Online Access: | https://acta.tums.ac.ir/index.php/acta/article/view/10956 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863921327472640 |
|---|---|
| author | Hamid Khederlou Reza Hassanzadeh-Makoui Vanoushe Azimi Pirsaraei |
| author_facet | Hamid Khederlou Reza Hassanzadeh-Makoui Vanoushe Azimi Pirsaraei |
| author_sort | Hamid Khederlou |
| collection | DOAJ |
| description |
Clopidogrel, a selective thienopyridine, is used for secondary prevention of major adverse cardiovascular events. Some studies have reported inflammatory arthritis as a rare adverse effect of Clopidogrel. A 47-year-old male underwent percutaneous coronary intervention and was subsequently prescribed a 600 mg loading dose of Clopidogrel, followed by a daily dose of 75 mg. After six days of taking Clopidogrel, the patient presented to the emergency department with right knee pain. The knee joint exhibited swelling, warmth, and tenderness, although there was no redness or crusting. After two and six days of hospitalization, despite receiving antibiotics and Indomethacin, he developed arthritis of the metacarpophalangeal and metatarsophalangeal joints, respectively. According to the laboratory investigation, cultures, synovial fluid analysis, and imaging, infectious, rheumatologic, and crystallopathy diseases were ruled out for the patient. Clopidogrel was discontinued, and the patient was switched to ticagrelor 90 mg twice daily. All symptoms and signs of joint inflammation had improved within five days of stopping the Clopidogrel. After one week and one and six months of follow-up, there has been no recurrence of symptoms.
|
| format | Article |
| id | doaj-art-6c7c07b4f8f748c1aa20314b3363e6b6 |
| institution | Kabale University |
| issn | 0044-6025 1735-9694 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Acta Medica Iranica |
| spelling | doaj-art-6c7c07b4f8f748c1aa20314b3363e6b62025-02-09T08:50:55ZengTehran University of Medical SciencesActa Medica Iranica0044-60251735-96942024-12-0162410.18502/acta.v62i4.17438Migratory Polyarthritis Associated With Clopidogrel: A Case ReportHamid Khederlou0Reza Hassanzadeh-Makoui1Vanoushe Azimi Pirsaraei2Department of Cardiology, Zanjan University of Medical Sciences, Zanjan, Iran.Department of Cardiology, Zanjan University of Medical Sciences, Zanjan, IranStudent Research Committee, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran Clopidogrel, a selective thienopyridine, is used for secondary prevention of major adverse cardiovascular events. Some studies have reported inflammatory arthritis as a rare adverse effect of Clopidogrel. A 47-year-old male underwent percutaneous coronary intervention and was subsequently prescribed a 600 mg loading dose of Clopidogrel, followed by a daily dose of 75 mg. After six days of taking Clopidogrel, the patient presented to the emergency department with right knee pain. The knee joint exhibited swelling, warmth, and tenderness, although there was no redness or crusting. After two and six days of hospitalization, despite receiving antibiotics and Indomethacin, he developed arthritis of the metacarpophalangeal and metatarsophalangeal joints, respectively. According to the laboratory investigation, cultures, synovial fluid analysis, and imaging, infectious, rheumatologic, and crystallopathy diseases were ruled out for the patient. Clopidogrel was discontinued, and the patient was switched to ticagrelor 90 mg twice daily. All symptoms and signs of joint inflammation had improved within five days of stopping the Clopidogrel. After one week and one and six months of follow-up, there has been no recurrence of symptoms. https://acta.tums.ac.ir/index.php/acta/article/view/10956ClopidogrelArthritisCase report |
| spellingShingle | Hamid Khederlou Reza Hassanzadeh-Makoui Vanoushe Azimi Pirsaraei Migratory Polyarthritis Associated With Clopidogrel: A Case Report Acta Medica Iranica Clopidogrel Arthritis Case report |
| title | Migratory Polyarthritis Associated With Clopidogrel: A Case Report |
| title_full | Migratory Polyarthritis Associated With Clopidogrel: A Case Report |
| title_fullStr | Migratory Polyarthritis Associated With Clopidogrel: A Case Report |
| title_full_unstemmed | Migratory Polyarthritis Associated With Clopidogrel: A Case Report |
| title_short | Migratory Polyarthritis Associated With Clopidogrel: A Case Report |
| title_sort | migratory polyarthritis associated with clopidogrel a case report |
| topic | Clopidogrel Arthritis Case report |
| url | https://acta.tums.ac.ir/index.php/acta/article/view/10956 |
| work_keys_str_mv | AT hamidkhederlou migratorypolyarthritisassociatedwithclopidogrelacasereport AT rezahassanzadehmakoui migratorypolyarthritisassociatedwithclopidogrelacasereport AT vanousheazimipirsaraei migratorypolyarthritisassociatedwithclopidogrelacasereport |